# Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction

> **NCT06061549** · PHASE1 · RECRUITING · sponsor: **Sardocor Corp.** · enrollment: 10 (estimated)

## Conditions studied

- Heart Failure, Diastolic
- Heart Failure With Preserved Ejection Fraction

## Interventions

- **BIOLOGICAL:** AAV1/SERCA2a

## Key facts

- **NCT ID:** NCT06061549
- **Lead sponsor:** Sardocor Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-24
- **Primary completion:** 2025-08
- **Final completion:** 2029-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06061549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06061549, "Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06061549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*